Pharma News India Weekly: Top Headlines & Industry Updates (09–14 March 2026)

📅 Published Date: 14 March 2026

The second week of March 2026 brought a mix of major policy shifts, legal victories, and rising cost pressures for the Indian pharmaceutical industry. The week saw a landmark decision from the Delhi High Court in the GLP-1 patent dispute, while the ongoing West Asia geopolitical conflict began impacting the pharma supply chain through rising API prices and logistical disruptions.

At the same time, the government stepped in with export relief measures, new trade corridors were announced, and regulators intensified scrutiny of pharmaceutical marketing and e-pharmacy pricing practices. From the booming GLP-1 drug market to global trade expansion and corporate developments, here is a complete roundup of the most important pharma industry developments from 9–14 March 2026.

Summary: Key Takeaways from the Week

Several important developments shaped the pharmaceutical industry this week.

  • GLP-1 Patent Battle: Delhi High Court allowed Dr. Reddy's Laboratories to manufacture and export semaglutide to countries where Novo Nordisk has no patent protection.
  • Raw Material Crisis: API and solvent prices surged 20–100% due to supply chain disruptions triggered by the Iran conflict.
  • Government Relief Measures: Authorities issued guidelines for handling stranded export cargo and considered financial support measures for exporters.
  • Trade Expansion: India–Uzbekistan pharmaceutical trade corridor launched to access the $7–10 billion Eurasian healthcare market.
  • Supply Chain Disruptions: Around 40,000–45,000 containers remain stranded globally while shipping costs continue rising.
  • Regulatory Crackdown: CDSCO banned surrogate advertising for GLP-1 drugs and NPPA launched a probe into dynamic pricing by e-pharmacies.
  • Corporate Developments: Kedaara Capital plans to sell Universal NutriScience for ₹3,000 crore while ACG joined the World Economic Forum’s Global Lighthouse Network.

GLP-1 Patent Battle: Delhi High Court Allows Dr. Reddy’s to Export Semaglutide

📅 Date: 9–10 March 2026

A major legal development occurred when the Delhi High Court permitted Dr. Reddy’s Laboratories to manufacture and export semaglutide to countries where Novo Nordisk does not hold patent protection.

The division bench of Justices C. Hari Shankar and Om Prakash Shukla dismissed Novo Nordisk’s appeal and upheld an earlier ruling allowing exports.

Key Legal Observations

The court noted that the company’s species patent could be vulnerable to revocation due to obviousness based on earlier genus patent teachings. Since Novo Nordisk’s earlier patent expired in 2024, the court stated that the current patent may not provide strong protection.

Market Impact

The decision comes shortly before the semaglutide patent expiry on March 20, 2026. Industry analysts expect over 50 branded generic versions to enter the Indian market soon.

Generic semaglutide treatments are expected to cost ₹3,000–₹5,000 per month, which could be three to five times cheaper than innovator brands, significantly expanding access to obesity and diabetes therapies.

Raw Material Crisis: API Prices Surge Due to Iran Conflict

📅 Date: 10–14 March 2026

The West Asia geopolitical conflict has begun impacting pharmaceutical manufacturing costs in India as raw material prices rise sharply.

Major API Price Increases

Industry reports indicate significant price increases between December 2025 and March 2026:

  • Thiocolchicide: +106%
  • Glycerin: +64%
  • Nimesulide: +53%
  • Deflazacort: +50%
  • Clobetasol Propionate: +47%
  • Paracetamol API: +26%
  • Diclofenac Sodium: +25–30%
  • Montelukast Sodium: +25–30%
  • Ciprofloxacin: +20–30%

Solvent Costs Also Rising

Solvents linked to crude oil derivatives also experienced price surges:

  • Isopropyl Alcohol (IPA): +20–30%
  • Propylene Glycol: +25–30%

These increases directly affect pharmaceutical manufacturing costs, especially for formulation companies.

Industry Requests Government Intervention

The Federation of Pharma Entrepreneurs has requested the National Pharmaceutical Pricing Authority (NPPA) to allow price revisions under DPCO 2013 Para 19, as companies struggle to absorb rising input costs.

Small and medium pharmaceutical manufacturers are particularly vulnerable due to strict price controls.

Supply Chain Disruptions: Containers Stranded and Freight Costs Surge

📅 Date: 8–14 March 2026

The closure of key maritime routes in the Middle East has caused major logistical disruptions for exporters.

Scale of Disruption

According to logistics reports:

  • 40,000–45,000 containers are currently stranded globally
  • Export cargo worth $1–1.5 billion is affected
  • Around 80% of containers are already in international waters

Freight Costs Rising

Shipping companies introduced additional charges:

  • War-risk surcharge: $3,000–$5,000 per container
  • Emergency bunker surcharge: $200 per TEU
  • India–Europe container charges: $160 per TEU

These costs significantly increase export expenses for pharmaceutical manufacturers.

Government Relief Measures

The Central Board of Indirect Taxes and Customs (CBIC) issued temporary guidelines allowing returning export cargo to be handled efficiently.

Key provisions include:

  • Back-to-town facility for exporters
  • Export incentive adjustments
  • Temporary port clearance procedures

Authorities are also considering Covid-era support measures, including loan moratoriums and extended export payment timelines.

Trade Expansion: India–Uzbekistan Pharma Corridor

📅 Date: 9 March 2026

India and Uzbekistan launched a pharmaceutical and nutraceutical trade corridor aimed at strengthening access to the Eurasian healthcare market.

The corridor aims to support:

  • Regulatory harmonization
  • Investment partnerships
  • Market access for Indian manufacturers
  • Supply chain collaboration

Launch Event

The initiative will be formally showcased during Pharma Eurasia 2026 in Tashkent, which will bring together global pharmaceutical manufacturers, regulators, and healthcare distributors.

Market Trends: GLP-1 Drug Market Surges

📅 Date: 8–14 March 2026

The GLP-1 agonist segment continues experiencing rapid growth in India.

Sales Growth

Market data indicates:

  • GLP-1 segment sales reached ₹1,446 crore in February 2026
  • Sales grew 177% year-on-year

Leading Products

Top performers include:

  • Mounjaro (tirzepatide) – ₹882 crore sales within 11 months
  • Semaglutide drugs – ₹445 crore annual sales

Mounjaro has remained India’s top-selling drug by monthly value for five consecutive months.

Regulatory Developments: CDSCO Ad Ban and E-Pharmacy Investigation

📅 Date: 11–12 March 2026

The Central Drugs Standard Control Organisation issued a strict advisory prohibiting surrogate advertising for GLP-1 drugs.

Pharmaceutical companies had been promoting obesity awareness campaigns featuring celebrities, which regulators believe indirectly promoted prescription medicines.

E-Pharmacy Pricing Under Investigation

The National Pharmaceutical Pricing Authority (NPPA) launched an investigation into e-pharmacy pricing practices, focusing on:

  • Location-based dynamic pricing algorithms
  • Inflated base prices with promotional discounts
  • Real-time monitoring through IPDMS systems

Corporate Developments in the Pharma Industry

Kedaara Capital Plans ₹3,000 Crore Nutraceutical Exit

Private equity firm Kedaara Capital is planning to sell Universal NutriScience at a valuation of around ₹3,000 crore.

The company currently owns 16 nutraceutical brands acquired from Sanofi India.

India’s nutraceutical industry is valued at around $8 billion and expected to grow at 11% CAGR through 2027.

ACG Joins WEF Global Lighthouse Network

ACG Packaging Materials became the first pharmaceutical packaging company to join the World Economic Forum’s Global Lighthouse Network.

The company’s Shirwal manufacturing facility achieved:

  • 40% reduction in lead times
  • 71% reduction in defects
  • 31% reduction in energy consumption
  • 34% improvement in on-time delivery

COVID-19 Vaccine Compensation Policy Ordered by Supreme Court

📅 Date: 10 March 2026

The Supreme Court directed the government to establish a no-fault compensation policy for individuals experiencing severe adverse effects following COVID-19 vaccination.

The court clarified that existing AEFI monitoring systems will continue to operate and vaccination safety data must be periodically published.

International Pharma News Updates

Global pharmaceutical companies also reported several regulatory approvals and clinical developments.

Regulatory Approvals

  • MHRA approved deuruxolitinib for alopecia areata
  • NHS approved fezolinetant for menopause-related hot flushes

Clinical Trial Developments

  • New cardiovascular and oncology trials announced
  • Microbiome therapy trials advancing in Europe
  • Biologic therapies showing improved outcomes in autoimmune diseases

These developments highlight the continued pace of innovation in the global pharmaceutical industry.

Frequently Asked Questions (FAQs)

What are the top pharmaceutical trends in 2026?

Major trends include the expansion of GLP-1 obesity drugs, rising API price pressures, digital transformation in pharma manufacturing, increasing regulatory scrutiny, and global export growth through free trade agreements.

What are the latest pharma industry updates this week?

Major updates include the Delhi High Court semaglutide ruling, API price increases due to geopolitical conflict, supply chain disruptions, the India–Uzbekistan pharma corridor launch, and CDSCO restrictions on GLP-1 promotional campaigns.

Where can I find weekly pharma industry news?

For regular pharmaceutical industry updates and weekly news summaries, visit

👉 greencrossindia.com/blog

Disclaimer and References

This article is prepared for informational and educational purposes only and summarizes pharmaceutical industry developments during 9–14 March 2026. The information has been compiled from publicly available reports and industry news sources including Economic Times, Business Line, Financial Express, Indian Express, Hindustan Times, Mint, Pharmarack market data, and international pharmaceutical news platforms. Readers are advised to verify official announcements from companies, regulators, and government authorities before making business, medical, or financial decisions.

APPLY FOR PCD PHARMA FRANCHISE

Read More on Our Social Platforms